Suven Pharmaceuticals to merge Cohance with itself

01 Mar 2024 Evaluate

Suven Pharmaceuticals has proposed scheme of amalgamation to merge Cohance Lifesciences (Cohance) with itself. This marks a pivotal moment in Suven's journey, underscoring its commitment to scaling, ensuring consistent earnings, fortifying its financial standing, and advancing towards forging leadership in the integrated CDMO space. Cohance is a leading CDMO and Merchant API platform with global leadership in select low-mid volume molecules as well as unique capabilities in the form of its antibody drug conjugates (ADC) platform. 

Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

Suven Life Sciences Share Price

168.45 -3.50 (-2.04%)
17-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.10
Dr. Reddys Lab 1272.00
Cipla 1496.95
Zydus Lifesciences 918.35
Lupin 2113.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×